Industry Forecast: Rare Kidney Diseases Market to Generate $14.21 Billion Revenue by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Rare Kidney Diseases Market Expected to Be in 2029?
The market size for dipeptide peptidase 4 inhibitors has been progressively increasing in the past few years. The market is projected to expand from $11.3 billion in 2024 to $11.81 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%. Several factors contributed to this growth in the historical period, including enhanced accessibility to diabetes therapies, broader usage of DPP-4 inhibitors beyond just type 2 diabetes, the rising implementation of DPP-4 inhibitors in triple therapy plans, an aging global population, amplified focus on healthcare and disease prevention, increased uptake of oral anti-diabetic medication, and heightened adoption in primary care environments.
In the coming years, the dipeptide peptidase 4 inhibitors market is predicted to experience consistent growth. It is anticipated to mature and reach a value of $14.21 billion by 2029, expanding at a compound annual growth rate (CAGR) of 4.7%. This expected growth within the projected period can be tied to factors such as a growing frequency of type 2 diabetes, a higher demand for efficient diabetes control, an aging demographic with rising diabetes rates, an enhanced focus on tailored healthcare, expanding acceptance of DPP-4 inhibitors in developing markets, a heightened frequency of diabetes and associated issues, and a rising need for diabetes oversight. The forecast period is set to witness trends like alliances, product sanctions, and ongoing research and development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15791&type=smp
What Are The Contributors To Demand In The Rare Kidney Diseases Market?
The rare kidney disease market is poised for significant growth, catalyzed by government initiatives and funding focused on kidney disorders. Defined as a form of financial support offered by the government to entities whose ideas or projects can ameliorate public services and bolster the economy, these initiatives are playing a key role in enhancing disease surveillance and bettering the lives of people affected by various kidney diseases. They hinge upon an extensive public health strategy that draws in other public health agencies and national entities. To illustrate, in July 2022, the United States House Committee on Appropriations of the House of Representatives launched several investment schemes aimed at enhancing kidney health. These included allocating $8.5 million to the Centers for Disease Control and Prevention’s (CDC) chronic kidney disease program, a move designed to bolster activities fostering regular kidney disease awareness, diagnosis, and treatment. Additionally, the National Living Donor Assistance Center received a further $1 million investment aimed at bolstering living donations, making a total of $8 million dedicated to ongoing innovation and research. Consequently, such government backing targeted at kidney disorders is playing a crucial role in propelling the rare kidney disease market.
The dipeptide peptidase 4 inhibitors market covered in this report is segmented –
1) By Type: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin, Others Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Channels
3) By Application: Type 2 Diabetes, Gestational Diabetes, Metabolic Syndrome, Other Applications
Who Are The Top-Ranked Companies In The Rare Kidney Diseases Market Today?
Major companies operating in the dipeptide peptidase 4 inhibitors market are Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Macleods Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corp., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Biocon Limited, LG Life Sciences, USV Private Limited, Sanwa Kagaku Kenkyusho Co. Ltd., Kowa Company Ltd
How Is Rare Kidney Diseases Market Adoption Varying Across Different Regions And Sectors?
Asia-Pacific was the largest region in the dipeptide peptidase 4 inhibitors market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dipeptide peptidase 4 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15791&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
